Ribosome quality control as drug target

Updated: 2026.11.18 5H ago 1 sources
Ribosomes are central to nearly every cell process and are already the target of many antibiotics, but we lack precise, clinically safe drugs that modulate human ribosomes or ribosome quality‑control pathways. Targeting regulatory levers (not wholesale translation shutdown) could yield therapies for cancer, neurodegeneration and aging — but raises toxicity, mitochondrial cross‑reactivity, and governance challenges. — Shifting drug discovery toward precision modulation of ribosome biology would reshape pharma pipelines, research funding, and regulatory standards for high‑risk molecular interventions.

Sources

Where are all the ribosome drugs?
Seeds of Science 2026.11.18 100% relevant
Author Jonathan Ouyang (founder of Collide Therapeutics) argues that existing ribosome drugs are 'sledgehammers' (antibiotics) and highlights omacetaxine and mitoribosome toxicity as concrete examples of both potential and risk.
← Back to all ideas